Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Methylprednisolone acetate
Drug ID BADD_D01434
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Adjunctive therapy for short-term administration in rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00979
MeSH ID D000077555
PubChem ID 5877
TTD Drug ID Not Available
NDC Product Code 50090-0436; 0009-0306; 0009-3475; 38779-0144; 50090-4802; 70518-2894; 50090-0312; 46439-8767; 0009-0274; 60219-1573; 25021-821; 0009-0280; 0009-3073; 50090-0556; 70518-2914; 63187-474; 50090-5894; 16714-089; 0703-0045; 25021-820; 0703-0043; 76420-081; 0703-0063; 70518-2965; 51927-0000; 16714-472; 51552-0958; 70518-2459; 70518-3071; 70121-1552; 50090-1823; 16714-473; 49452-4688; 0703-0051; 70121-1573; 51662-1429; 0009-0026; 76420-260; 0703-0031; 10695-041; 76420-262; 16714-090; 22552-0023; 63275-9942; 68788-8082; 60219-1574; 70121-1574; 70518-2915; 50090-2098; 65089-0016; 16714-088; 82298-117; 52128-148
Synonyms Methylprednisolone Acetate | Methylprednisolone-21-acetate | Methylprednisolone 21 acetate | Acetyl-Methylprednisolone | Acetyl Methylprednisolone | Depo-Medrone | Depo Medrone | Depo-Medrol | Depo Medrol | Methylprednisolone Acetate, (11beta,16beta)-isomer | Methylprednisolone Acetate, (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C24H32O6
CAS Registry Number 53-36-1
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)C)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abscess sterile08.01.05.008--Not Available
Acne23.02.01.001--Not Available
Affective disorder19.04.04.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Alkalosis hypokalaemic14.01.02.002--Not Available
Alopecia23.02.02.001--
Amenorrhoea05.05.01.002; 21.01.02.001--
Amnesia17.03.02.001; 19.20.01.001--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Anxiety19.06.02.002--
Arachnoiditis12.02.04.002; 17.06.01.001--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthropathy15.01.01.003--Not Available
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Atrophy08.03.04.001--Not Available
Benign intracranial hypertension17.07.02.001--Not Available
Blindness06.02.02.001; 17.17.01.003--Not Available
Blood calcium increased13.11.01.003--Not Available
Blood potassium decreased13.11.01.010--Not Available
Blood urea increased13.13.01.006--Not Available
Bradycardia02.03.02.002--Not Available
Calcinosis08.03.04.002--Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages